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ABSTRACT 
Aberrant increased expression and activation of receptor tyrosine kinases occur frequently in 
human carcinomas.  Several small molecules targeting receptor tyrosine kinases, which have 
crucial roles in the growth factor signaling that promote tumor progression in various 
malignancies, including non-small cell lung cancer (NSCLC), are currently in clinical 
development. Therapeutic strategies include inhibition of growth factor tyrosine kinase 
function. Drugs of this type include those that target the epidermal growth factor receptor 
tyrosine kinase, those that target vascular endothelial growth factor receptors tyrosine kinase 
and those that target anaplastic lymphoma receptor tyrosine kinase. In this review we first 
discuss the role of receptor tyrosine kinases in human malignancies, and focus on discussing 
the potential use of epidermal growth factor receptor tyrosine kinase inhibitors and the 
vascular endothelial growth factor receptors tyrosine kinase inhibitors in NSCLC. In addition, 
we discuss the contribution of growth factor receptor tyrosine kinase inhibitors to the 
clinically observed resistance, and toxicity.  
Introduction 
Non-small cell lung cancer (NSCLC) is the leading cause of 
cancer-related deaths worldwide and constitutes 
approximately 85% of all lung cancers [1, 2]. The vast 
majority of patients with advanced NSCLC are not curable 
and overall five year survival is 14% (Stage IIIA), 5% (Stage 
IIIB), and 1% (Stage IV) [3]. Chemotherapy, a category 
of cancer treatment that uses chemical substances, especially 
one or more anti-cancer drugs is beneficial for patients with 
locally advanced and metastatic disease. Numerous phase III 
studies have determined the superiority of systemic 
chemotherapy over best supportive care. Platinum based 
chemotherapy has been widely accepted as the standard of 
care for the initial treatment of advanced NSCLC [4]. 
However first line chemotherapy is modest at best and with 
substantial toxicity. Clearly a different approach is needed for 
the treatment of NSCLC.  
Protein kinases are key regulators of cell function that 
contribute one of the largest and most functionally diverse 
genes families. By adding phosphate groups to substrate 
proteins, they direct the activity, localization and overall 
function of many proteins, and serve to orchestrate the activity 
of almost all cellular processes. Kinases are particularly 
prominent in signal transduction and co-ordination of complex 
functions such as the cell cycle. Tyrosine kinase forms a 
significant share of all oncoproteins thus they take centre stage 
as possible targets for cancer therapy.  The recent discovery of 
tyrosine kinase driver mutations as a therapeutic target for 
cancer and ATP-binding domain of tyrosine kinases have led 
to clinical development of many tyrosine kinase inhibitors in 
various malignancies, including lung cancer [5-7].  
In recent years, knowledge about the roles of protein tyrosine 
kinases in progression, metastasis, and growth at the 
metastatic site in NSCLC and the understanding of NSCLC as 
a heterogeneous disease with several genetic subsets have also 
received considerable attention, and have led to an 
improvement of patients treatment outcome. In the following 
we will discuss tyrosine kinase, epidermal growth factor 
receptor tyrosine kinase inhibitors and vascular endothelial 
growth factor receptor inhibitors in NSCLC.  
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Tyrosine Kinase 
A tyrosine kinase is an enzyme that can transfer 
a phosphate group from ATP to a protein in a cell. It functions 
as an "on" or "off" switch in many cellular functions. 
Tyrosine kinases are a subclass of protein kinase
kinases are a subgroup of the larger class of
kinases that attach phosphate groups to other amino acids 
(serine and threonine) [8, 9]. Phosphorylation
kinases is an important mechanism in communicating signals 
within a cell (signal transduction) and regulating cellular 
activity, such as cell division. Protein kinases can become 
mutated, stuck in the "on" position, and cause unregulated 
growth of the cell, which is a necessary step fo
development of cancer. Therefore, kinase inhibitors, such 
as imatinib, are often effective cancer treatments. Most 
tyrosine kinases have an associated 
phosphatase, which removes the phosphate group. Tyrosine 
Figure 1: Tyrosine kinase signaling and associated growth factor receptors.
factor receptor such as EGFR and VEGFR authophosphorylates tyrosine residues in its cytoplasmic domain, which serve as a dock
sites for the assembly of protein complexes that transduce EGF or VEGF signals to generate specific biological responses.
EPIDERMAL GROWTH FACTOR RECEPTOR 
TYROSINE KINASE INHIBITORS 
Epidermal growth factor receptor (EGFR) belongs to a family 
of receptor tyrosine kinases (RTKs) that include 
EGFR/ERBB1, HER2/ERBB2/NEU, HER3/ERBB3, and 
HER4/ERBB4. In normal cells, the binding of ligands, such as 
epidermal growth factor (EGF), induces a conformational 
change that facilitates receptor homo- 
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resulting in autophosphorylation of specific tyrosine residues 
of the cytoplasmic kinase domain. Besides these 
phosphorylation sites for regulation of their own kinase 
activity, other phosphorylation sites of kinases are being used 
to control protein interactions. The activated receptor recruits 
interacting proteins that bind to certain phosphorylation sites. 
Recruited and phosphorylated signaling proteins are 
subsequently able to phosphorylate other proteins [10, 11]. 
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are frequently dysregulated. EGFR is involved in regulation of 
numerous oncogenic functions such as cell proliferation, 
survival, differentiation, neovascularisation, invasion and 
metastasis. Activating mutations in EGFR lead to constitutive 
tyrosine kinase activation and oncogenic transformation of 
lung epithelial cells in vitro [16, 17]. One major approach to 
EGFR inhibition is the use of small-molecule inhibitors of 
intracellular tyrosine kinase domain which block the 
extracellular domain of the receptor. Gefitinib and erlotinib 
are orally administered EGFR-tyrosine kinase inhibitors, 
which compete with ATP for binding to the tyrosine
domain. 
EGFR-TKIs Resistant mutations 
EGFR overexpression has been associated with a number of 
cancers, including lung cancer. Its constant activation was due 
to the involvement of somatic mutations. Most patients with 
NSCLC were reported to have tumour associated EGFR 
mutations [18, 19]. These mutations occur within EGFR exons 
18–21, which encodes a portion of the EGFR kinase domain 
(Figure 2). Exon 19 deletions or exon 21 L858R point 
mutations are the most frequently recorded in patients with 
NSCLC [21, 22]. Resistance to kinase inhibitors targeting 
epidermal growth factor receptor (EGFR) tyrosine kinase was 
reported in patients with non-small cell lung cancer; 
documented resistance cases were associated with primary 
resistance mutations such as exon 20 insertions which 
comprise approximately 4–9.2% of all EGFR
tumors [23, 24]. Most EGFR exon 20 inse
between amino acids 767 to 774 of exon 20, within the loop 
that follows the C-helix of the kinase domain of EGFR [25]. 
Decreased sensitivity to reversible and irreversible EGFR
TKIs [26-29], and to mutant-selective covalent EGFR
Figure 2:EGFR mutations. Exons 18–21 of the EGFR kinase domain are depicted. 
with sensitivity to EGFR TKIs. Mutations listed below the schematic are associated with EGFR TKI resistance
from://www.mycancergenome.org 
Adverse events associated with EGFR-TKI Therapy
Although much less toxic than the treatments they replaced, 
EGFR-TKIs are generally better tolerated than cytotoxic 
chemotherapy. In randomized phase III clinical trials, many 
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to display lack of response when treated with gefitinib or 
erlotinib [32, 33].  In retrospective and prospective analyses of 
patients with NSCLCs harboring typical EGFR exon 20 
insertions, most displayed progressive disease in the 
treatment with gefitinib or erlotinib or afatinib [34]. It is not 
worthy that N771GY and A767
somatic insertion mutations in exon 20, and S768N, a 
missense mutation, were all identified in the African American 
cohort [35, 36]. In East Asian patients, S768I, a somatic 
EGFR mutation, was reported with evidence, suggesting a 
potential role in EGFR TKI resistance [37, 38]. The 
mutational status seems also to vary between the primary lung 
tumor and the corresponding metast
mutations would be present in the primary lung tumor but 
appear to be absent in the metastases. According to several 
studies, the discordance rate of 
between 16.2% to 32.5% [39, 40]. Another most common 
cause of TKI resistance is the development of a second EGFR 
mutation known as T790M. 
methionine at amino acid position 790 (T790M), as the second 
mutation in EGFR, is the most common resistance 
mechanism. The  EGFR T790M mutation 
in 50% to 60% of patients initially diagnosed with an EGFR
activating or – sensitizing mutation (either an exon 19 deletion 
or exon 21 L858R mutation) who experience disease 
progression with a first-
aberrations that may give rise to EGFR TKI resistance include 
PIK3CA mutations, EMT or MET amplification, or 
conversion to small cell lung cancer histology [43, 44].
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TKI are rash-like events that erupts most often on the face but 
can also be seen on the chest, back, trunk, and limbs, and it 
was observed in IPASS (66.2%), First SIGNAL (72.4%), 
WJTOG 3405 (76%), and NEJ002 (71%) studies in patients 
treated with gefitinib, in OPTIMAL (73%), EURTAC (80%) 
studies in patients treated with erlotinib and in LUX-Lung 3 
(89.1%), LUX-Lung 6 (80.8%) studies in patients treated with 
afatinib [47-51]. In the BR.21 trial, grade 3/4 rash was 
reported to occurr in 9% patients with a median time to onset 
of 8 days [52].  
Diarrhea is another common class effect of these drugs. It can 
be seen at any time during treatment with EGFR inhibitors. 
Severe diarrhea occurred in about 3% to 6% of the patients 
taking erlotinib or gefitinib in phase III trials. Other less 
common side effects can be nausea and vomiting, anorexia, 
and stomatitis. 
Rare but statistically significant occurrences of interstitial lung 
disease (ILD) have been reported in randomized Phase III 
clinical trials. In studies of gefitinib, ILD occurred in 0.3% to 
1% of the US population and in about 2% of Japanese patients 
[53]. ILD rates in the BR.21 trial erlotinib trial were less than 
1% [54]. 
VASCULAR ENDOTHELIAL GROWTH FACTOR 
RECEPTOR TYROSINE KINASE INHIBITORS  
Vascular endothelial growth factor (VEGF), a mitogen 
specific for vascular endothelial cells, plays a key role in 
angiogenesis. VEGF-related angiogenic signal is mediated by 
kinase domain receptor (KDR) and Fms-like tyrosine kinase 
(Flt-1), which have intracellular tyrosine kinase activity [55]. 
Multiple tyrosine kinase receptors which appear to have 
important roles in the generation of new vessels from pre-
existing ones for rapid tumor growth and, as such, represent 
reasonable targets for chemotherapy strategy. Multi-targeted 
tyrosine kinase inhibitors (cediranib, motesanib, sorafenib, 
sunitinib, vandetanib, nintedanib, pazopanib, linifanib, 
axitinib, etc) have been studied in many randomized 
controlled trials for treatment of advanced non-small cell lung 
cancer (NSCLC) [56]. A meta-analysis of randomized 
controlled trials compare the efficacy and toxicity of 
chemotherapy plus multi-targeted TKI with chemotherapy 
alone in patients with advanced NSCLC; therapy consisting of 
chemotherapy plus multi-targeted TKI was reported by Xiao et 
al. to have specific advantages over chemotherapy alone in 
terms of PFS and ORR [57]. The key tyrosine kinase target 
that has generated the most interest through targeting crucial 
steps of angiogenesis is VEGFR. FDA approved and those 
under investigation are orally active small molecule inhibitors 
which target VEGF family of tyrosine kinases and a wide 
spectrum of other tyrosine kinase receptors.  
Challenges Associated with VEGFR-TKIs Therapy 
Survival of endothelial cells is highly related to growth factor 
signaling under normal physiological conditions. Inhibitors of 
angiogenesis via inhibition of VEGFR related tyrosine kinase 
are capable of affecting signaling pathways in endothelial cells 
and thus might elicit toxicities as a result of decreased 
endothelial cell renewal capacity [58]. A meta-analysis of 10 
randomized controlled trials showed that the use of vascular 
endothelial growth factor receptor (VEGFR) tyrosine kinase 
inhibitors was associated with an increased risk of fatal 
adverse events. Roberto, et al. [59] reported the incidence and 
risk of hepatic toxicity in patients receiving VEGFR-TKIs 
through a large up-to-date meta-analysis of available clinical 
trials. It is known that, one kinase is able to activate several 
downstream signaling pathways. By inhibition of a kinase 
with a tyrosine kinase inhibitor, downstream signaling 
pathways can be deactivated. This might perturb specific 
biological outcomes which are not intended to adjust. It has 
been shown that specific kinases are involved in the normal 
physiology of certain organs such as kidneys and the thyroid 
gland. It has been suggested that specific toxicities, like 
nephrotic syndrome and fatigue, might be related to 
interference of these inhibitors with the normal function of 
these organs [60, 61].  Besides the vascular effects observed 
with inhibition of the vascular endothelial growth factor 
(VEGF) pathway (i.e., hypertension and hemorrhage), direct 
functional effects on the heart have been observed for several 
small molecule TKIs; sorafenib has been associated with 
cardiac ischemic/infarct events in as many as 2.9% of patients 
[62]. Effects on cardiac function have also been associated 
with sunitinib which has been associated with increases in 
patients with left ventricular ejection fractions below the lower 
limit of normal leading to congestive heart failure in some 
cases [63].  
Summary 
A number of studies of the molecular mechanisms of lung 
cancer has led to the description and understanding of several 
genetic abnormalities. Among these, the identification of a 
number of potentially targetable driver mutations in growth 
related protein kinases, especially tyrosine kinases in lung 
cancer and have led to the discovery of several potential 
molecular targets for therapeutic design, such as epidermal 
growth factor receptor (EGFR) and vascular endothelial 
growth factor receptor (VEGFR) [64, 65]. The development of 
effective chemotherapeutics which target growth factor 
receptor tyrosine kinases in non-small cell lung cancer has 
significantly improves patients’ treatment outcome. However, 
resistance to tyrosine kinase inhibitors in NSCLC is an 
increasingly recognized issue. Future priorities for the 
development of growth factor receptor tyrosine kinase agents 
in NSCLC include the development of drugs that effectively 
inhibit a network of growth factor induced signaling pathways. 
Also, further biological studies are required to better 
understand the pathogenesis of lung cancer, especially non-
small cell lung cancer, in order to improve treatment response. 
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